Arthneeti
Latest: Aarti Pharma Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
AP

Aarti Pharma

Q1 FY27Pharmaceuticals & Biotechnology

Aarti Pharma Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹839
Market cap₹7.4K Cr
P/E34.4
Updated25 Aug 2026
Read4 min read

Aarti Pharma Q1 FY27 key numbers

Revenue
Overall company targeting all three segments (Xanthine, API, CDMO) to grow beyond INR1,000 crores each.

As stated in Aarti Pharma's Q1 FY27 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.

The short version

API segment targeted to achieve INR1,000 crores plus revenue with current and ongoing debottlenecking in steroid and anticancer blocks and new Block 5 line. Aarti Pharmalabs targets significant growth across all three segments (Xanthine derivatives, API & Intermediates, CDMO/CMO), each aiming to surpass INR1,000 crores revenue.

From Aarti Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Good growth
  • API segment targeted to achieve INR1,000 crores plus revenue with current and ongoing debottlenecking in steroid and anticancer blocks and new Block 5 line.
  • Xanthine derivatives expect revenue between INR900 crores to INR1,100 crores this year, with volume ramp-up from 6,000 to 9,500 tonnes in the next couple of years.
  • CDMO/CMO segment aims for 40-50% growth this year, targeting to exceed 25-30% of overall company sales with 57 active projects (37 commercial).
  • Overall company targeting all three segments (Xanthine, API, CDMO) to grow beyond INR1,000 crores each.
  • New product launches in anticancer and antidiabetic drugs expected to contribute to growth.

2 more points from Aarti Pharma's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aarti Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Completed debottlenecking of steroid block at Unit 4, Tarapur, increasing capacity by 33%.
  • Incremental capacity for Xanthine derivatives commercialized at end of Q1 FY '27; ramp-up expected over next quarters aiming for 80%+ utilization by FY '28.
  • Both phases of Atali Block 1 (440 kL reactor capacity) becoming fully operational in Q2 FY '27, focusing on CDMO/CMO intermediate manufacturing.
  • Announced INR 149 crores capex for Block 2 at Atali with 400+ kL reactor capacity; groundbreaking expected in Q3 FY '27 with 12–15 months completion.
  • Block 2 dedicated to specific CDMO projects; more cost-effective than multipurpose block and a key step toward INR 1,000 crores CDMO/CMO revenue goal.

2 more points from Aarti Pharma's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aarti Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • The company is working with 22 customers in the CDMO/CMO segment.
  • There are currently 57 active projects, with 37 in commercial stages and 20 in developmental stages.
  • The CDMO segment is expected to achieve 40-50% growth this year.
  • Visibility exists for multiple dedicated CDMO projects, with 3-4 projects planned for a new dedicated block.
  • The company is confident of reaching INR 1,000 crores revenue in the CDMO/CMO segment.

2 more points from Aarti Pharma's call on order book

Create a free account to keep reading this call

What the Q1 FY27 call signalled

3 of 4 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

Aarti Pharma — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Aarti Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aarti Pharma and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aarti Pharma Q1 FY27 results?

API segment targeted to achieve INR1,000 crores plus revenue with current and ongoing debottlenecking in steroid and anticancer blocks and new Block 5 line. Aarti Pharmalabs targets significant growth across all three segments (Xanthine derivatives, API & Intermediates, CDMO/CMO), each aiming to surpass INR1,000 crores revenue.

What is Aarti Pharma share price analysis?

Aarti Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 34.4 with a market cap of ₹7,407 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharma planning capital expenditure?

Completed debottlenecking of steroid block at Unit 4, Tarapur, increasing capacity by 33%.

Keep Aarti Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.